GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NeurogesX Inc (OTCPK:NGSX) » Definitions » Owner Earnings per Share (TTM)

NeurogesX (NeurogesX) Owner Earnings per Share (TTM) : 0.00 (As of Dec. 2011)


View and export this data going back to . Start your Free Trial

What is NeurogesX Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

NeurogesX's Owner Earnings per Share (TTM) ended in Dec. 2011 was $0.00. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for NeurogesX's Owner Earnings per Share (TTM) or its related term are showing as below:



NGSX's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.13
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

NeurogesX's Earnings per Share (Diluted) for the six months ended in Dec. 2011 was $-2.15. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2011 was $-2.15. It's PE Ratio ratio for today is At Loss.

NeurogesX's EPS without NRI for the six months ended in Dec. 2011 was $-2.15. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2011 was $-2.15. It's PE Ratio without NRI ratio for today is At Loss.


NeurogesX Owner Earnings per Share (TTM) Historical Data

The historical data trend for NeurogesX's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeurogesX Owner Earnings per Share (TTM) Chart

NeurogesX Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeurogesX Semi-Annual Data
Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeurogesX's Owner Earnings per Share (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, NeurogesX's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeurogesX's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NeurogesX's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where NeurogesX's Price-to-Owner-Earnings falls into.



NeurogesX Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

NeurogesX's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income -49.55
Depreciation, Depletion and Amortization 0.38
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.31
Change In Working Capital -0.66
Shares Outstanding (Diluted Average) 23.01

1. Start with "Net Income" from income statement. NeurogesX's Net Income for the trailing twelve months (TTM) ended in Dec. 2011 was $-49.55 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. NeurogesX's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2011 was $0.38 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. NeurogesX's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2011 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.31 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

NeurogesX's 5-Year Average Maintenance Capital Expenditure = $0.31 Mil

5. "Change In Working Capital" is from cashflow statement. NeurogesX's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2011 was $-0.66 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. NeurogesX's Shares Outstanding (Diluted Average) for the months ended in Dec. 2011 was 23.011 Mil.

NeurogesX's Onwer Earnings Per Share for Dec. 2011 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -49.545 +0.376+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.3142+-0.662)/23.011
=0.00

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=0.005/0.00
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


NeurogesX Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of NeurogesX's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


NeurogesX (NeurogesX) Business Description

Traded in Other Exchanges
N/A
Address
NeurogesX, Inc. was incorporated in California as Advanced Analgesics, Inc. on May 28, 1998 and changed its name to NeurogesX, Inc. in September 2000. In February 2007, it reincorporated into Delaware. It is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. It is assembling a portfolio of pain management product candidates based on known chemical entities to develop innovative new therapies that might offer substantial advantages over currently available treatment options. The Company's initial focus is on the management of chronic peripheral neuropathic pain conditions. The Company's first commercial product, Qutenza, the first prescription strength capsaicin product is a dermal delivery system designed to treat certain neuropathic pain conditions and was approved by the U.S, Food and Drug Administration, or FDA in November 2009 for the management of neuropathic pain associated with postherpetic neuralgia, or PHN. It is currently preparing to commercialize Qutenza in the United States with its own sales force and that Qutenza would be commercially available in the United States in the first half of 2010. Qutenza is a non-narcotic analgesic formulated in a localized treatment patch containing an 8% concentration of synthetic capsaicin. Capsaicin is released from the patch and, with the aid of penetration enhancers, penetrates into the skin during application without significant absorption of capsaicin into the bloodstream. The users of Qutenza are unlikely to experience the common central nervous system side effects of systemically administered drugs used to treat neuropathic pain such as anti-convulsants, anti-depressants and opioids and the potential for abuse and addiction associated with some of these drugs. It is currently evaluating the nature, scope and timing of continued development of Qutenza to support the potential for label expansion in the United States. Areas of potential focus for label expansion include HIV-distal sensory neuropathy, or HIV-DSP, also known as HIV-associated neuropathy, or HIV-AN, painful diabetic neuropathy, or PDN, and potentially other neuropathic pain indications. It expects that Qutenza would compete against, and may be used in combination with, well-established products currently used both on and off-label in its target indications. The most directly competitive currently marketed products in the United States are Lidoderm, an FDA-approved 5% lidocaine topical patch for the treatment of PHN marketed by Endo Pharmaceuticals, and Lyrica, an oral anti-convulsant, marketed by Pfizer for use in the treatment of PHN. Regulation by governmental authorities in the United States and other countries is a significant factor in the development, manufacture and marketing of pharmaceuticals.
Executives
Ron Martell officer: President and CEO PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Stephen F Ghiglieri officer: Exec. V.P., COO & CFO C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Robert Nelsen director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Steven H Nelson director 21650 OXNARD STREET, WOODLAND HILLS CA 91367
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Bradford S Goodwin director 5000 SHORELINE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Jean Jacques Bienaime director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Anthony A Ditonno director, officer: President and CEO C/O OXYGEN BIOTHERAPEUTICS, INC., ONE COPLEY PARKWAY, STE. 490, MORRISVILLE NC 27560
Jeffrey K Tobias officer: CMO, EVP Research & Deve C/O NEUROGESX INC, 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070
Moshe Arkin 10 percent owner, other: also member of 10% owner group 6 HACHOSHLIM ST., HERZELIA L3 4672406
Keith Crandell 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Clinton Bybee 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Steven Lazarus 10 percent owner 8755 WEST HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners V Llc 10 percent owner C/O ARCH VENTURE PARTNERS, 8755 W. HIGGINS AVE. #1025, CHICAGO IL 60631

NeurogesX (NeurogesX) Headlines

From GuruFocus

NeurogesX Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-08-2010

NeurogesX Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-13-2010

NeurogesX Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 08-11-2010